INDIA – Viatris and India’s Biocon Biologics are debating whether to further integrate their already deeply entwined biosimilar businesses into a US$10 billion standalone company, according to Moneycontrol, an Indian…
Read MoreViatris and Biocon consider merger of their biosimilars into a US$10B standalone company
